Law360, New York (August 16, 2011, 1:18 PM ET) -- Abbott Laboratories on Friday continued its bid to protect the market for cholesterol drug Simcor, filing another patent infringement suit in Delaware against generic-drug maker Teva Pharmaceutical Industries Ltd.
Abbott and Abbott Respiratory LLC lodged the complaint over Teva's bid for U.S. Food and Drug Administration approval to market a generic Simcor, which contains niacin and simvastatin.
The plaintiff sued Teva in March and an additional three times in 2010 over Simcor. Friday's suit references Teva's bid for a green light to market tablets containing 500...
Abbott Targets Teva Over Latest Simcor ANDA
To view the full article, take a free trial now.
